TP-1 demonstrated the ability to effectively impede the progression of HCC by inhibiting hypoxia inducible factor 1 subunit alpha/vascular endothelial growth factor (HIF-1α/VEGF) mediated angiogenesis and boosting immunity [121, 122]. This evidence concerns the gene HIF1A and hepatocellular carcinoma.